RecruitingNot ApplicableNCT06952101

A Global, Integrated, Personalized, Stage-related, Multimodal Therapeutic Approach for Rectal Adenocarcinoma Based on Organ Sparing and Mininvasivity

INTERPRETE: a Global, Integrated, Personalized, Stage-related, Multimodal Therapeutic Approach for Rectal Adenocarcinoma Based on Organ Sparing and Mininvasivity


Sponsor

Fondazione del Piemonte per l'Oncologia

Enrollment

200 participants

Start Date

Apr 30, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

A phase II, single-center, non-profit, interventional study on patients affected by rectal adenocarcinoma. Patients will be stratified into three groups based on pre-treatment clinical stage. The study investigates and may propose a comprehensive, stage-specific, multimodal approach to rectal adenocarcinoma, with a focus on organ preservation even in early stages (cT1-2N0). When organ-sparing strategies are not feasible, the approach prioritizes minimally invasive techniques (laparoscopic and robotic) to reduce the physical, psychological, and quality-of-life impact on patients.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This international study is evaluating a personalized, minimally invasive approach to treating rectal cancer — including organ-preserving strategies that may avoid the need for a permanent colostomy bag. The study focuses on patients who respond well to radiation and chemotherapy, potentially allowing surgery to be avoided or minimized. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with rectal adenocarcinoma at a stage where organ-preserving treatment is being considered - Your tumor was either removed endoscopically (high-risk early stage), or your cancer had a strong response (complete or near-complete) to chemoradiation therapy **You may NOT be eligible if...** - Your cancer did not achieve adequate shrinkage after chemoradiation - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURESparing Approach

Accurate staging with Pelvic MRI, CT scan, PET total body have to be performed before local excision in order to exclude false positive mesorectal lymph nodes. Subsequent Wait and See (W\&S) approach could be proposed.

PROCEDUREexperimental chemoradiotherapy

Participants with cT2N0 rectal tumors are typically candidates for upfront surgical resection. The investigators propose an alternative approach based on experimental chemoradiotherapy (spCRT). Literature suggests that pathologic complete response (pCR) rates after CRT are significantly higher than the 25% described for intermediate-advanced tumors. The investigators will assess clinical complete response (cCR) or complete metabolic response (cMR) through a multidisciplinary restaging process, including MRI, PET, thorax-abdomen CT scan, ERUS, and rectoscopy. In participants achieving cCR or cMR, a Watch and Wait (W\&S) strategy or Local Excision/Transanal Minimally Invasive Surgery (LE/TAMIS) may be proposed to avoid the physical and psychological consequences of major surgery, followed by a rigorous surveillance program.

PROCEDUREStandard Chemotherapy

Tumors will be initially treated with standard CRT (stCRT). Patients who reach cCR-cMR at restaging they are already candidates to sparing approaches with W\&S/LE/TAMIS according to Multicentric Resarch Study Protocol


Locations(1)

Department of Surgical Oncology - FPO-IRCCS Institute for Cancer Research and Treatment

Candiolo, Turin, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06952101


Related Trials